NY AG Lands Final Approval for $17.3 Billion Opioid Settlement
By Dean Seal
New York's attorney general said Friday that final approval has been granted for $17.3 billion in settlements with drug makers and pharmacies over the opioid crisis.
The approvals resolve cases from multiple states accusing Teva Pharmaceuticals and Allergan as well as CVS and Walgreens of downplaying the risk of painkillers and perpetuating the deadly opioid epidemic.
The settlement deals will become effective in the coming weeks and the settlement funds will start becoming available to state and local governments by the end of the year.
New York is set to receive more than $1 billion and has already started receiving payments from Teva for the trial premium as part of the state's previous landmark liability verdict against the company, the New York AG's office said.
"These funds will help with opioid abatement, education, and treatment efforts in our communities," Attorney General Letitia James said.
Write to Dean Seal at dean.seal@wsj.com
(END) Dow Jones Newswires
June 09, 2023 10:24 ET (14:24 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
Is the Era of Volatility-Suppressing Policies Possibly Over?
-
5 Undervalued Stocks That Crushed Earnings for Q1 2024
-
What Does Nvidia’s Stock Split Mean for Investors?
-
After Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Baidu Stock a Buy, a Sell, or Fairly Valued?
-
Why Stocks Are Hitting Record Highs—and What Could Send Them Back to Earth
-
5 Stocks to Buy While They’re Trading at Big Discounts
-
Markets Brief: Tech Stocks Lead Ahead of Nvidia Earnings
-
Live Nation: Breakup Sought by Department of Justice Probably Wouldn’t Affect Fair Value Much
-
After Earnings, Is Applied Materials Stock a Buy, Sell, or Fairly Valued?
-
The Best Energy Stocks to Buy
-
Snowflake Earnings: Mixed News, But Signs of Stability
-
Nvidia Earnings: AI Demand Smashes Expectations Again
-
After Earnings, Is Walmart Stock a Buy, a Sell, or Fairly Valued?
-
Target Earnings: Margins Hold Up, but Top Line Constrained by Weak Discretionary Spending
-
Is Berkshire Hathaway’s Mystery Stock a Buy?